切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2015, Vol. 11 ›› Issue (06) : 682 -684. doi: 10.3877/cma.j.issn.1673-5250.2015.06.002

所属专题: 文献

专家述评

宫颈癌的化疗
高雨农1,*,*()   
  1. 1. 100142 北京大学肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室
  • 收稿日期:2015-06-10 修回日期:2015-10-30 出版日期:2015-12-01
  • 通信作者: 高雨农

Chemotherapy of cervical cancer

Yunong Gao1()   

  1. 1. Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China
  • Received:2015-06-10 Revised:2015-10-30 Published:2015-12-01
  • Corresponding author: Yunong Gao
  • About author:
    Corresponding author: Gao Yunong, Email:
引用本文:

高雨农. 宫颈癌的化疗[J/OL]. 中华妇幼临床医学杂志(电子版), 2015, 11(06): 682-684.

Yunong Gao. Chemotherapy of cervical cancer[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(06): 682-684.

宫颈癌的主要治疗方案是手术和放疗,近年由于对宫颈癌综合治疗方案的广泛应用,特别是手术技术的改进,保留生育手术的兴起,使宫颈癌化疗逐渐受到重视。宫颈癌的化疗包括同步放化疗、术前新辅助化疗、术后辅助化疗及姑息化疗。新辅助化疗虽然在临床中应用广泛,但其疗效迄今仍尚未确定,而同步放化疗却得到了临床的进一步肯定。宫颈癌姑息治疗中的化疗,不能改善患者的远期生存质量。因此,化疗仍然是宫颈癌治疗的辅助手段。

The main treatments of cervical cancer include surgical operation and radiotherapy. As multimodality treatment is widely used recently, the chemotherapy of cervical cancer is becoming more and more important, especially because of the improvements of surgical technique and surgical operation of retaining fertility. The chemotherapy protocols of cervical cancer treatment include concurrent radiochemotherapy preoperative, preoperative new adjuvant chemotherapy, postoperative complementary chemotherapy, and palliative chemotherapy. Although new adjuvant chemotherapy is being widely used now, the efficacy is still not exact. Concurrent radiochemotherapy has gotten further affirmation. The chemotherapy of palliative treatment can not improve the long-term survival. In summary, the chemotherapy is still an assistant method of cervical cancer treatments.

[1]
周晖,彭永排,俞进,等. 《2014年NCCN宫颈癌临床实践指南》解读[J].实用妇产科杂志,2014, 30(6):167-168.
[2]
Kantardzie N. Concurrent chemoradiation for cervical cancer: results offive randomized trials[J]. Med Arh, 2010, 64(6):368-371.
[3]
Frei E. Clinical cancer research:an embattled specics[J]. Cancer, 1982, 50(10):1979-1992.
[4]
Gadducci A, Sartori E, Maggino T, et al. Pathological response on surgical samples is an independent prognostic variable for patients with stage ⅠB2-ⅡB cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy:an Italian multicenter retrospective study (CTF Study)[J]. Gynecol Oncol, 2013, 131(3):640-644.
[5]
林仲秋.《FIGO 2015妇癌报告》解读连载一:宫颈癌诊治指南解读[J]. 中国实用妇科与产科杂志,2015, 31(11):981-985.
[6]
Wu LZ, Li CM, Liu WW, et al. Study on the molecule mechanisms efficacy of neoadjuvant chemotherapy in middle and advanced cervical cancer[J]. Chin J Laborat Diagn, 2010, 14(5):738-741.
[7]
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer:a systematic review and meta analysis of individual patient data from 18 randomized trials[J]. J Clin Oncol, 2008, 26(35):5802-5812.
[8]
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage ⅠB cervical carcinoma[J]. N End J Med, 1999, 340(15):1154-1157.
[9]
Whitney CW, Sause W, Bundy BN, et al.Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ⅡB-ⅣA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. Clin Oncol, 1999, 17(5):1339-1342.
[10]
Lanciano R, Calkins A, Bundy BN, et al.Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study[J]. Clin Onco1, 2005, 23(33):289-292.
[11]
Piver MS, Ghamande SA, Eltabbakh GH.First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix :a phase Ⅱ study[J]. Gynecol Oncol, 1999, 75(3):334-337.
[1] 石皆春, 范子玉, 邢燕. 不同筛查方法预警宫颈原位腺癌的效能[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 575-581.
[2] 张少华, 林爱齐, 张玉, 董晓云, 刘红英. HLAIL基因多态性及其与复发性自然流产的相关性[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 251-259.
[3] 高伟聪, 李丽, 张中华, 朱向辉, 刘素巧. 宫颈癌患者糖调节受损对改良根治术后2年内复发的影响作用[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 231-237.
[4] 李玉萍, 马会, 禹航. 腹腔镜下子宫动脉阻断术联合子宫肌瘤切除术治疗子宫肌瘤临床疗效[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 238-244.
[5] 蒋冉, 邹彩艳, 桑谊荃. 宫颈上皮内瘤变Ⅲ患者血清性激素水平及其与高危型人乳头瘤病毒感染的关系[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 683-688.
[6] 魏丽坤, 张旭红, 罗营, 薛凤霞, 王颖梅, 宋学茹, 田丽娜, 张艳芳, 王艳霞, 田文艳. 卵巢子宫内膜异位囊肿发生恶变并发盆腔脓肿1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 696-702.
[7] 武渊, 朱必清, 何丹, 王海蓉, 李倩. 采取调强放疗联合后装治疗宫颈癌患者的预后模型及危险分层系统构建[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 734-744.
[8] 罗文斌, 韩玮. 胰腺癌患者首次化疗后中重度骨髓抑制的相关危险因素分析及预测模型构建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 357-362.
[9] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10] 刘柏隆, 周祥福. 女性尿失禁吊带手术并发症处理的经验分享[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 127-127.
[11] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[12] 李晓阳, 刘柏隆, 周祥福. 大数据及人工智能对女性盆底功能障碍性疾病的诊断及风险预测[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 549-552.
[13] 张桂萍, 丘勇林, 湛绮婷, 孙乐栋. 晚期非小细胞肺癌血清Ape1/Ref-1对放射性肺损伤发生的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 519-523.
[14] 高红琴, 陈晨, 陆瑞科, 王小雨, 张敏, 李少华, 郝梨岚, 黄新程, 关凌耀, 张韵红. 外阴阴道假丝酵母菌病对女性阴道-宫颈菌群的影响研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(06): 720-725.
[15] 黎璞, 生秀杰. 妊娠合并子宫颈癌的管理[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 202-208.
阅读次数
全文


摘要